Clinical Use of Methadone

References

• Chen K K. Pharmacology of methadone and related compounds. Ann NY Acad Sci 1948; 51: 83–97
   PubMed Web of Science ®Google Scholar
• Gouldin W M, Kennedy D T, Small R E. Methadone: History and Recommendations for use in analgesia. Am Pain Soc Bull 2000; 10(5)8–10
   Google Scholar
• Lenz G R, Walters D E, Evans S M, Hopfinger A G. Open-chain analgesics. Opiates. Academic Press, New York, NY 1986
   Google Scholar
• Kreek M J. Methadone-related opioid agonist pharmacotherapy for heroin addiction. Ann NY Acad Sci 2000; 909: 186–216
   PubMed Web of Science ®Google Scholar
• Way W L, Fields H L, Way E L. Opioid analgesics and antagonists. Basic and Clinical Pharmacology, 7th ed., B G Katzung. Appleton and Lange, Stamford, CT 1998
   Google Scholar
• Reisine T, Pasternak G. Opioid analgesics and antagonists. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 9th ed., L E Limbird, J G Hardman. McGraw-Hill, New York, NY 1996; 521–555
   Google Scholar
• Beaver W T, Wallenstein S L, Houde R W, Rogers A. A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly and of orally and parenterally administered methadone. Clin Pharmacol Ther 1967; 8: 415–426
   PubMedGoogle Scholar
• Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993; 52: 137–147
   PubMed Web of Science ®Google Scholar
• Nilsson M I, Meresaar U, Aggard E. Clinical pharmacokinetics of methadone. Acta Anaesthesiol Scand 1982, Suppl 74: 66–69
   Google Scholar
• Ettinger D S, Vitale P J, Trump D L. Important clinical pharmacologic considerations in the use of methadone in cancer patients. Cancer Treat Rep 1979; 63: 457
   PubMedGoogle Scholar
• Symonds P. Methadone and the elderly. BMJ 1977; 1: 512
   PubMedGoogle Scholar
• Sawe J, Hansen J, Ginman C, et al. Patient-controlled dose regimen of metha-done for chronic cancer pain. BMJ 1981; 282: 771–773
   PubMed Web of Science ®Google Scholar
• Ventafridda V, Ripamonti C, Bianci M, et al. A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage 1986; 1: 203–207
   PubMedGoogle Scholar
• Bruera E, Watanabe S, Fainsinger R L, et al. Custom-made capusles and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 1995; 62: 141–146
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Zecca E, Bruera. An update on the clinical use of methadone for cancer pain. Pain 1997; 70: 109–115
   PubMed Web of Science ®Google Scholar
• DeConno F, Groff L, Brunelli C, et al. Clinical experience with oral administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996; 14: 1836–1842
   Google Scholar
• Payte J T. Methadone maintenance treatment: the first thirty years. J Psychoactive Drugs 1997; 29(2)149–153
   PubMed Web of Science ®Google Scholar
• Mercadente S. Opioid rotation for cancer pain. Rationale and clinical aspects Cancer 1999; 86(9)1856–1866
   Google Scholar
• Dickenson H A. NMDA-receptor antagonists in the treatment of chronic pain. Acta Anaesthesiol Scand 1997; 41: 112–115
   PubMedGoogle Scholar
• Ebert B, Anderson S., Kroesgaard P, Larsen. Ketobemidone, methadone and pethidine are non-competitive N-methyl-d-asparate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995; 187: 165–168
   PubMed Web of Science ®Google Scholar
• Crews J C, Sweeny N J, Denson D D. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Cancer 1993; 72(7)2266–2272
   PubMedGoogle Scholar
• Bennett G H. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA receptor. J Pain Symptom Manage 2000; 19(1 Suppl)S2–6
   Google Scholar
• Hewitt D J. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain 2000; 16(2)S73–79
   PubMedGoogle Scholar
• Inturrisi C E, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 1972; 13: 923–930
   PubMed Web of Science ®Google Scholar
• Sawe J. High-dose morphine and methadone in cancer patients. Clinical pharm-acokinetic consideration of oral treatment. Clin Pharmacokin 1986; 11: 87–106
   PubMed Web of Science ®Google Scholar
• Meresaar U, Nilsson M I, Holmstrand J, Anggard E. Single dose pharma-cokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur J Clin Pharmacol 1981; 20: 473–478
   PubMed Web of Science ®Google Scholar
• Inturrisi C E, Verebely K. The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther 1972; 3(5, part 1)633–637
   Google Scholar
• Dyer K R, Foster D JR, White J M, Somogyi A A, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparision of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 1999; 65(6)685–694
   PubMed Web of Science ®Google Scholar
• Paalzow L, Nilsson L, Stenberg P. Pharmacokinetic basis for optimal metha-done treatment of pain in cancer patients. Acta Anaesthesiol Scand 1982, Suppl 74: 55–58
   Google Scholar
• Inturrisi C E, Colburn W A, Kaiko R F, Houde R W, Foley K M. Pharmaco-kinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987; 41: 392–401
   PubMed Web of Science ®Google Scholar
• Gourlay G K, Cherry D A, Cousins M J. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 1986; 25: 297–312
   PubMed Web of Science ®Google Scholar
• Moolchan E T, Umbricht A, Epstein D. Therapeutic drug monitoring in metha-done maintenance: choosing a matrix. J Addict Dis 2001; 20(2)55–73
   PubMed Web of Science ®Google Scholar
• Paalzow L. Pharmacokinetic aspects of optimal pain treatment. Acta Anaes-thesiol Scand 1982, Suppl 74: 37–39
   Google Scholar
• Inturrisi C E, Portenoy R K, Max M B, et al. Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther 1990; 47: 565–577
   PubMed Web of Science ®Google Scholar
• Gourlay G K, Wilson P R, Glynn C J. Pharmacodynamics and pharmacokinetics of methadone during the perioperative period. Anesthesiology 1982; 57(6)458–467
   PubMedGoogle Scholar
• Nilsson M. J. Clinical pharmacokinetics of methadone. Academic thesis of Uppsala University, UppsalaSweden 1982
   Google Scholar
• Plummer J L, Gourlay G K, Cherry D A, et al. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988; 33: 313–322
   PubMed Web of Science ®Google Scholar
• Dole V P, Kreek M J. Methadone plasma level: sustained by a reservoir of drug in the tissue. Proc Natl Acad Sci USA 1973; 70: 10
   PubMed Web of Science ®Google Scholar
• Robinson A E, Williams F M. The distribution of methadone in man. J Pharm Pharmacol 1971; 23: 353–358
   PubMed Web of Science ®Google Scholar
• Olsen G D. Methadone binding to human plasma proteins. Clin Pharmacol Ther 1973; 14: 338–343
   PubMed Web of Science ®Google Scholar
• Romach M K, Piafsky K M, Abel J G, et al. Methadone binding to orosomucoid (X1-acid-glycoprotein) determinant of free fraction in plasma. Clin Pharmacol Ther 1981; 29: 211–217
   PubMed Web of Science ®Google Scholar
• Abramson F P. Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein. Clin Pharmacol Ther 1982; 32: 652–658
   PubMed Web of Science ®Google Scholar
• Calvo R, Aguirre C, Trodniz Lopz I F, Garrido M J. Alpha1-acid glycoprotein and serum protein binding of heroin addicts during withdrawal. Proc VI World Congress on Clinical Pharmacology and Therapeutics, Buenos Aires, Argentina 1996; 174
   Google Scholar
• Wolff K, Rostami-Hodjegan A, Shires S, et al. The pharmacokinetics of metha-done in healthy subjects and opiate users. Br J Clin Pharmacol 1997; 44: 325–334
   PubMed Web of Science ®Google Scholar
• McEvoy G K. AHFS Drug Information 2001. American Society of Health-Systems Pharmacists, Bethesda, MD 2001
   Google Scholar
• Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9(2)365–373
   PubMed Web of Science ®Google Scholar
• Moody D E, Alburges M E, Parker R J, Collins J M, Strong J M. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997; 25(12)1347–1353
   PubMed Web of Science ®Google Scholar
• Beckett A H, Taylor J H, Casy A F, Hassan M MA. The biotransformation of methadone in man: synthesis and identification of a major metabolite. J Pharm Pharmacol 1968; 20: 754–762
   PubMed Web of Science ®Google Scholar
• Eap C B, Broly F, Mino A, et al. Cytochrome P450 2D6 genotype and metha-done steady-state concentrations. J Clin Psychopharmacol 2001; 21(2)229–234
   PubMed Web of Science ®Google Scholar
• Verebely K, Volavaka J, Mule S, Resnick R. Methadone in man: Pharma-cokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975; 18(2)180–190
   PubMedGoogle Scholar
• Bellward G, Warren P M, Howald W, Axelson J E, Abbott F S. Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses. Clin Pharmacol Ther 1977; 22(1)92–99
   PubMedGoogle Scholar
• Baselt R C, Bickel M H. Biliary excretion of methadone by the rat: identification of a para-hydroxylated major metabolite. Biochem Pharmacol 1973; 22: 258–66
   Google Scholar
• Baumann P, Tinguely D, Schopf J. Increase of alpha-1-acid glycoprotein after treatment with amitriptyline. Br J Clin Pharmacol Ther 1982; 14: 102–103
   PubMed Web of Science ®Google Scholar
• Novick D M, Kreek M J, Fanizza A M, et al. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 1981; 30: 353–362
   PubMedGoogle Scholar
• Kreek M J, Schecter A J, Gutjahr C L, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980; 5: 197–205
   PubMed Web of Science ®Google Scholar
• Concilus R., Denson D D, Knarr D., Warden G., Raj P P. Continuous intravenous infusion of methadone for control of burn pain. J Burn Care Rehabil 1989; 10: 406–409
   PubMedGoogle Scholar
• Jacobson L, Chabal C, Brody M C, Ward R J, Ireton R C. Intrathecal methadone and morphine for postoperative analgesia: a comparison of the efficacy, duration, and side effects. Anesthesiology 1989; 70(5)742–746
   PubMedGoogle Scholar
• Jacobson L, Chabal C, Brody M C, Ward R J, Wasse L. Intrathecal methadone: a dose-response study and comparison with intrathecal morphine 0.5 mg. Pain 1990; 43: 141–148
   PubMedGoogle Scholar
• Lacy C F, Armstrong L L, Goldman M P, Lance L L. Methadone. Drug Information Handbook, 9th ed. Lexi-Comp, Cleveland, OH 2001, 2002
   Google Scholar
• Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain, a retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996; 78(4)852–857
   PubMed Web of Science ®Google Scholar
• Mercadente S, Casuccio A, Calderone L. Rapid switiching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999; 17(10)3307–3312
   PubMedGoogle Scholar
• Hunt G, Bruera E. Respiratory depression in a patient receiving oral methadone in cancer pain. J Pain Symptom Manage 1995; 10(5)401–404
   PubMedGoogle Scholar
• Manfredi P L, Gonzales G R, Cheville A L, Kornick C, Payne R. Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy. J Pain Symptom Manage 2001; 21(2)169–174
   PubMed Web of Science ®Google Scholar
• Forman W B. Opioid analgesic drugs in the elderly. Clin Geriatr Med 1996; 12(3)489–500
   PubMedGoogle Scholar
• Dyer K R, White J M. Patterns of symptom complaints in methadone maintenance patients. Addiction 1997; 92(11)1445–1455
   PubMed Web of Science ®Google Scholar
• Zucchero F J, Hogan M J, Schultz C. D. Evaluations of Drug Interactions. First DataBank, St. Louis, MO 1999
   Google Scholar
• Kreek M J, Gutjahr C L, Garfield J W, Bowen D V, Field F H. Drug interactions with methadone. Ann NY Acad Sci 1976; 281: 350–371
   PubMed Web of Science ®Google Scholar
• Mendelson J, Jones R T, Welm S, Brown J, Batki S L. Buprenorphine and naloxone interactions in methdone maintenance patients. Biol Psychiatry 1997; 41: 1095–1101
   PubMed Web of Science ®Google Scholar
• Kreek M J. Plasma and urine levels of methadone Comparison following four medication forms used in chronic maintenance treatment NY State. J Med 1973; 73: 2773–2777
   Google Scholar
• Kreek M J, Garfield J W, Gutjahr C L, Giustil L M. Rifampin-induced methadone withdrawal. N Engl J Med 1976; 294(20)1104–1106
   PubMed Web of Science ®Google Scholar
• Hunter J, Chasseaud L. F. Clinical aspects of microsomal enzyme induction. Progress in drug metabolism. Wiley, New York, NY, 133
   Google Scholar
• Tong T G, Pond S M, Kreek M J, Jaffery N F, Benowitz N L. Phenytoin-induced methadone withdrawal. Ann Intern Med 1981; 94: 349–351
   PubMed Web of Science ®Google Scholar
• Bertschy G, Baumann P, Eap C B, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994; 16: 42–45
   PubMed Web of Science ®Google Scholar
• De Maria P A, Serota R D. A therapeutic use of the methadone fluvoxamine drug interaction. J Addict Dis 1999; 18(4)5–12
   Google Scholar
• Herrlin K, Segerdahl M, Gustafsson L L, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000; 356(16)2069–2070
   PubMedGoogle Scholar
• Bauman J H, Kimlblatt B J. Cimetidine as an inhibitor of drug metabolism: therapeutic implications and review of literature. Drug Intell Clin Pharm 1982; 16: 380–386
   PubMedGoogle Scholar
• Gourevitch M N. Interactions between methadone and medications used to treat HIV: a review. Mt. Sinai J Med 2000; 67(5–6)429–436
   PubMedGoogle Scholar
• Cobb M N, Desai J, Brown L S, Zannikos P N, Rainey P M. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998; 63(6)655–662
   PubMed Web of Science ®Google Scholar
• Mercadente S, Casuccio A, Agnello A, et al. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol 1998; 16(11)3656–3661
   PubMedGoogle Scholar
• Cherny N J, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995; 76: 1283–1293
   PubMed Web of Science ®Google Scholar
• Coyle N, Adelhart J, Foley K M, et al. Character of terminal illness in the advanced cancer patient; pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990; 5: 83–93
   PubMedGoogle Scholar
• Management of Cancer Pain. Clinical Practice Guidelines. U.S. Department of Health and Human Services, Rockville, MD 1994, AHCPR Pub No. 94–052.
   Google Scholar
• Lawlor P G, Turner K S, Hanson J, Bruera E D. Dose ratio between morphine and methadone in patients with cancer pain. Cancer 1998; 82(6)1167–1173
   PubMed Web of Science ®Google Scholar
• Denson D D, Concilius R R, Gregg R V, Crews J C. The correlation between predicted and measured patients specific analgesic concentrations after intravenous titration: a guide for initial intravenous requirements with methadone. J Clin Pharmacol 1990; 30: 1049–1054
   PubMedGoogle Scholar
• Ripamonti C, Groff L, Brunelli C, et al. Switching from morphine to oral meth-adone in treating cancer pain: what is the equianalgesic dose ratio??. J Clin Oncol 1998; 16(10)3216–3221
   PubMed Web of Science ®Google Scholar
• Ayonrinde O T, Bridge D T. The rediscovery of methadone for cancer pain management. Med J Aust 2000; 173: 536–540
   PubMed Web of Science ®Google Scholar
• Strain E C, Stitzer M L, Liebson I A, Bigelow G E. Methadone dose and treatment outcome. Drug Alcohol Depend 1993; 33: 105–117
   PubMed Web of Science ®Google Scholar
• Strain E C, Bigelow G E, Liebson I A, Stitzer M L. Moderate vs. high-dose meth-adone in the treatment of opioid dependence. JAMA 1999; 281(11)1000–1005
   PubMed Web of Science ®Google Scholar
• Maddux J F, Desmond D P, Esquivel M. Rapid admission and retention on meth-adone. Am J Drug Alcohol Abuse 1995; 21(4)533–547
   PubMed Web of Science ®Google Scholar
• Jaffe J H, Senay E C. Methadone and l-methadyl acetate. JAMA 1971; 216(8)1303–1305
   PubMedGoogle Scholar
• Kosten T R, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus meth-adone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181(6)358–364
   PubMed Web of Science ®Google Scholar
• Johnson R E, Fudala P J, Jaffe J H. A controlled trial of buprenorphine for opioid dependence. JAMA 1992; 267: 2750–2755
   PubMed Web of Science ®Google Scholar
• Johnson R E, Chutuape M A, Strain E C, Walsh S L, Stitizer M L, Bigelow G E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343(18)1290–1297
   PubMed Web of Science ®Google Scholar
• Effective Medical Treatment of Opiate Addiction. NIH Consens Statement Nov 17–19, 1997; 15(6)1–38
   Google Scholar
• Substance Abuse and Mental Health Services (SAMSHA) Press Release. New Federal Regulations issued to improve methadone treatment. January 17, 2001, National Alliance for Methadone Advocates: Available at http://www.methadone.org Accessed June 18, 2001.
   Google Scholar